Moderna and Merck previously reported five-year follow-up data from their Phase 2b KEYNOTE-942 trial, showing that the ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

The pharmaceutical sector continues to attract investor attention, with recent clinical developments highlighting the ...

The fate of an important breakthrough in cancer immunotherapy treatment remains in the balance following an announcement earlier this week that the Department of Health and Human Services will cancel ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...